Ovidio F. C.
- Country
- Spain
- Department
- Medical Oncology
Research Overview
- Phase II Study of Sasanlimab and Sacituzumab Govitecan in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Patients
- Phase 2 Open‑Label Single‑Arm Study of Enfortumab Vedotin Plus Pembrolizumab for Bladder Preservation in Patients with Muscle‑Invasive Bladder Cancer
- Phase II Open-Label Evaluation of Sacituzumab Govitecan in Patients with Unresectable Locally Advanced or Metastatic Urothelial Carcinoma
Data & Insights
Has run more than one trial at 74 of 221 partner sites.
Specializations
Gastrointestinal oncology
The clinical research profile includes a strong focus on gastric cancer, gastroesophageal junction adenocarcinoma, esophageal carcinoma, and colorectal cancer, with attention to both advanced disease and perioperative treatment settings.
- Metastatic colorectal cancer
- Advanced gastric and gastroesophageal junction adenocarcinoma
- Esophageal squamous cell carcinoma
- Pancreatic adenocarcinoma
Research activity also extends to gastrointestinal cancer-associated thromboembolism and treatment-related complications in digestive tract malignancies.
Thoracic malignancies
Another key area of interest is non-small cell lung cancer, including locally advanced, metastatic, and resectable disease, as well as biomarker-defined subgroups such as RET fusion-positive NSCLC and PD-L1-selected disease.
- Advanced or metastatic non-small cell lung cancer
- Resectable non-small cell lung cancer
- Small cell lung cancer
- RET fusion-positive NSCLC
The portfolio reflects interest in immunotherapy, antibody-drug conjugates, and combination strategies in lung cancer care.
Urologic cancers
The investigator is involved in studies of urothelial carcinoma and bladder cancer, covering both muscle-invasive and non-muscle-invasive settings, along with locally advanced and metastatic disease.
- Urothelial carcinoma
- Muscle-invasive bladder cancer
- Non-muscle invasive bladder cancer
- Locally advanced or metastatic urothelial cancer
There is also engagement with renal cell carcinoma and metastatic castration-resistant prostate cancer, broadening the scope of genitourinary oncology research.
Hematologic malignancies
The hematology portfolio includes trials in myelodysplastic syndromes, chronic lymphocytic leukemia, multiple myeloma, and follicular lymphoma, with emphasis on relapsed, refractory, and newly diagnosed settings.
- Myelodysplastic syndrome
- Chronic lymphocytic leukemia
- Relapsed or refractory multiple myeloma
- Follicular lymphoma
Additional interest is seen in chronic myeloid leukemia and supportive care approaches for treatment-related cytopenias.
Supportive care and non-oncologic conditions
Beyond oncology, the investigator is involved in studies addressing venous thromboembolism, chemotherapy-induced thrombocytopenia, ulcerative colitis, septic shock, and acute pancreatitis.
- Venous thromboembolism prevention
- Chemotherapy-induced thrombocytopenia
- Inflammatory bowel disease
- Critical care and pancreatitis complications
This includes therapeutic interest in anticoagulation, hematologic support, and complication prevention in complex cancer and non-cancer settings.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.